The Age Specific Microbiome of Children with Milk, Egg, and Peanut Allergy

Punita Ponda,Jane E. Cerise,Brianne Navetta-Modrov,Jamie Kiehm,Grace M. Covelli,Jared Weiss,Annette T. Lee
DOI: https://doi.org/10.1016/j.anai.2024.04.028
2024-05-02
Abstract:Background Immune regulation by gut microbiota is affected by dysbiosis and may precede food allergy onset. Prior studies lack comparisons stratified by age and clinical phenotype. Objective The primary objective was to assess the microbiome of children with food allergy (< 3years, 3-18years) compared to similar aged children without food allergy. Methods A real-world prospective cross-sectional study performed from 2014-2019 recruited children highly likely to have milk, egg or peanut allergy defined by history and serum IgE or confirmed by food challenge. 16S ribosomal RNA sequencing identified stool microbial DNA. Alpha- and beta-diversity was compared between food-allergic groups and healthy controls stratified by age. Differential abundance for non-a-priori taxa was accepted at absolute fold-change > 2 and q-value < 0.05. Results 70 patients were included(56 food-allergic;14 healthy controls). Groups were not significantly different in age, gender at birth, race, mode of delivery, breastfeeding duration, or antibiotic exposure. Younger food-allergic children had similar alpha-diversity compared to controls. Beta diversity was significantly different by age(p=0.001). There was differential abundance of several a-priori(p<0.05) taxa (including Clostridia) only in younger children. Both a-priori (including Coprococcus, Clostridia) and non-a-priori(q<0.05) Acidobacteria_Gp15,Aestuariispira, Tindallia and Desulfitispora were significant in older food-allergic children, especially with peanut allergy. Conclusion Dysbiosis associates with food allergy, most prominent in peanut-allergic older children. Younger children with and without food allergy have fewer differences in gut microbiota. This correlates with clinical observations of persistence of peanut allergy, and improved efficacy and safety of oral immunotherapy in younger children. Age under 3 should be considered when initiating therapeutic interventions.
immunology,allergy
What problem does this paper attempt to address?